Trial Profile

Beta-hCG + EryThropoietin in Acute Stroke

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 10 Jun 2009

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NTx 265 (Primary)
Indications Ischaemic stroke
Focus Therapeutic Use
Acronyms BETAS-b
Sponsors Trillium Therapeutics Inc

Most Recent Events

15 May 2009 Stem Cell Therapeutics announced that the U.S. FDA has issued a formal letter confirming immediate removal of the clinical hold placed on the Phase IIb stroke trial.
18 Sep 2008 Stem Cell Therapeutics has received a verbal request (from the US FDA) not to begin trial recruitment yet as data from an unrelated foreign study have highlighted safety concerns associated with epoetin-alfa.
11 Jun 2008 New trial record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com